According to GlobalData’s medical device pipeline database, 20 Buccal delivery devices are in various stages of development globally. GlobalData’s report provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.
Of these devices, nine are in active development, while the remaining 13 are in an inactive stage of development. There are three products in the early stages of development, and the remaining six are in the late stages of development.
Buccal delivery devices are used to administer drugs within or through buccal mucosa to affect local or systemic pharmacological actions.
Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.
Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed Buccal delivery pipeline devices are all expected to be approved within the next ten years.
Currently, private organizations, public entities and institutions are working on the development of Buccal delivery devices. Overall, most of these Buccal delivery pipeline devices are being developed by private entities.
Key players involved in the active development of Buccal delivery include Karessa Pharma, Insys Therapeutics, IntelGenx, AFYX Therapeutics, BioXcel Therapeutics, Callitas Therapeutics, Hebrew University of Jerusalem, Hikma Pharmaceuticals, Medlab Clinical and Mycrodose Therapeutics.
For a complete picture of the developmental pipeline for Buccal delivery devices, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.